EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab

Giovanna Lucia Piazzetta, Nadia Lobello, Emanuela Chiarella iD, Alberta Rizzuti iD, Corrado Pelaia iD, Girolamo Pelaia iD, Nicola Lombardo iD

Journal of Personalized Medicine · 19.09.2023 · 13 (9) · 1404

DOI: 10.3390/jpm13091404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 19.09.2023. Verfasst von Giovanna Lucia Piazzetta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology Head and Neck Surgery, Department Medical and Surgical Sciences, University "Magna Græcia", 88100 Catanzaro, Italy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory disease linked to type 2 inflammation. Several biologics have demonstrated therapeutic potential for the treatment of this pathology in which IL-4, IL-5 and IL-13 represent the major cytokines involved in the control of eosinophilic respiratory inflammation. 25% of CRSwNP patients relapse after the use of oral glucocorticoids or after surgery and often require several surgeries during their lifetime. In our study we enrolled 14 patients, 11 male and 3 female. The inclusion criteria were: age ≥ 18 years; confirmed diagnosis of chronic rhinosinusitis with severe nasal polyposis; disease severity with NPS Nasal Polyposis Endoscopic Score total score ≥ 5 and/or SNOT-22 ≥ 50; previous treatment failure due to lack of efficacy or discontinuation of systemic corticosteroid therapy and/or non-response or recurrence following surgery. The results presented in this study showed the ability of Dupilumab to improve all the parameters analysed. In particular, statistically significant data were obtained for NPS, SNOT-22, NRS, and IgE in patients exposed to Dupilumab treatment for 24 weeks, highlighting the ability of Dupilumab to produce clinical benefit in CRWwNP patients. In light of these data, the administration of dupilumab every two weeks represents a valid clinical strategy that ENT specialists can adopt for the treatment of adults with inadequately controlled CRSwNP.

Schlagwörter

Stichwörter der Autor:innen

IgESino Nasal Outcome Test-22 (SNOT-22)chronic rhinosinusitiscytokinesdupilumabinflammatory diseasenasal polypsnasal polyps score (NPS)numeric rating scale (NRS)peripheral eosinophiliatype 2 inflammation

Autor:innen und Institutionen

  • Otolaryngology Head and Neck Surgery, Department Medical and Surgical Sciences, University "Magna Græcia", 88100 Catanzaro, Italy.
  • Laboratory of Molecular Haematopoiesis and Stem Cell Biology, Department of Experimental and Clinical Medicine, University "Magna Græcia", 88100 Catanzaro, Italy.
  • Department of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.

ORCID-Profile: Emanuela Chiarella, Alberta Rizzuti, Corrado Pelaia, Girolamo Pelaia, Nicola Lombardo

Zitieren

APA

Piazzetta, G. L., Lobello, N., Chiarella, E., Rizzuti, A., Pelaia, C., Pelaia, G., & Lombardo, N. (2023). Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab. Journal of Personalized Medicine, 13(9), 1404. https://doi.org/10.3390/jpm13091404

Vancouver

Piazzetta GL, Lobello N, Chiarella E, Rizzuti A, Pelaia C, Pelaia G, et al. Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab. Journal of Personalized Medicine. 2023;13(9):1404. doi:10.3390/jpm13091404

BibTeX
@article{Piazzetta2023,
  author = {Piazzetta, Giovanna Lucia and Lobello, Nadia and Chiarella, Emanuela and Rizzuti, Alberta and Pelaia, Corrado and Pelaia, Girolamo and Lombardo, Nicola},
  title = {Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {9},
  pages = {1404},
  doi = {10.3390/jpm13091404}
}
Kostenlos starten →